Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке: https://scidar.kg.ac.rs/handle/123456789/10904
Назив: Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis
Аутори: Jovic, Zorica
Jankovic, Slobodan
Ruzic Zecevic, Dejana
Milovanovic, Dragan
Stefanovic, Srdjan
Folic, Marko
Milovanovic, Jasmina
Kostic M.
Часопис: European Journal of Drug Metabolism and Pharmacokinetics
Датум издавања: 9-апр-2019
Сажетак: © 2018, Springer Nature Switzerland AG. Second-generation triazoles were developed in response to the quest for more efficacious and safer therapeutic options for the treatment of severe systemic aspergillosis and candidiasis. These agents include voriconazole, posaconazole, isavuconazole, and ravuconazole. The aim of this review was to present and compare the pharmacokinetic characteristics of second-generation triazoles for the treatment of invasive aspergillosis and candidiasis, emphasizing their clinical implications. The MEDLINE, Scopus, EBSCO, Google Scholar, and SCIndeks databases were searched using advanced search options, including the names of second-generation triazoles and pharmacokinetic terms as keywords. The intravenous administration of voriconazole, posaconazole, and isavuconazole results in stable pharmacokinetics of these drugs, with mostly predictable variations influenced by common and usually known factors in routine clinical settings. The high oral bioavailability of isavuconazole and, to some extent, voriconazole makes them suitable for intravenous-to-oral switch strategies. Except for intravenous voriconazole (due to the accumulation of the toxic vehicle hydroxypropyl betadex), dose reduction of second-generation triazoles is not needed in patients with renal failure; patients with hepatic insufficiency require dose reduction only in advanced disease stages. The introduction of therapeutic drug monitoring could aid attempts to optimize the blood concentrations of triazoles and other drugs that are known to or that possibly interact, thus increasing treatment efficacy and safety. There is a need for new studies that are designed to provide useful data on second-generation triazole pharmacokinetics, particularly in special circumstances such as central nervous system and ocular infections, infections in newborns and infants, and in subjects with genetic polymorphisms of metabolizing enzymes.
URI: https://scidar.kg.ac.rs/handle/123456789/10904
Тип: review
DOI: 10.1007/s13318-018-0513-7
ISSN: 03787966
SCOPUS: 85054555906
Налази се у колекцијама:Faculty of Medical Sciences, Kragujevac

Број прегледа


Број преузимања


Датотеке у овој ставци:
Датотека Опис ВеличинаФормат 
  Ограничен приступ
29.86 kBAdobe PDFСличица

Ставке на SCIDAR-у су заштићене ауторским правима, са свим правима задржаним, осим ако није другачије назначено.